Colorectal cancer
Conditions
Interventions
Day 1 Palonosetoron 0.75mg/body and dexamethasone 12mg/body should be administered 30 minutes prior to chemotherapy Day 2-3 Dexamethasone 4mg/body should be administered orally.
Sponsors
Gifu University graduate school of medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pathologically colorectal cancer 2. Age; more than 20 years-old at registration 3. Performance status of 0-2 4. Patients receiving moderate emetic chemotherapy including oxaliplatin or irinotecan 5. Patients who has vomited(including dry-vomiting) or been administered additional rescue 6. Adequate organ function 7. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Severe complication(s), e.g., congestive cardiac failure, coronary failure, cardiac infarction, angina pectoris, arrhythmia, cerebrovascular accident, active gastrointestinal tract ulcer, diabetes, renal failure, hepatic failure, active hepatitis or hepatic cirrhosis. 2. Symptomatic brain metastasis 3.Epilepsy patient treated with antiepileptic agent, exclusing being stable clinically 4.Combination radiotherapy 5. History of serious drug hypersensitivity for 5-HT3RA or dexamethasone. 6. History of administration of palonosetoron 7. Pregnant, nursing mothers or man who don't agree with contraception 8.Unsuitable patients judged by investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete Response rate | — |
Countries
Japan
Contacts
Public ContactTakao Takahashi
Gifu University graduate school of medicine Department of surgical oncology
Outcome results
None listed